Compound Profile
BPC 157
Synthetic peptide (gastric-derived sequence)
BPC 157 is a synthetic 15 amino acid peptide studied mainly in animal models for gut healing, tendon and ligament repair, and inflammation modulation; human clinical trial data is essentially absent and its FDA compounding status is unresolved pending a July 2026 PCAC review.
Last reviewed:
C PreliminaryMonograph visual
BPC 157
Generated profile category visual
Where to go next — guides & comparisons
Continue reading
- If you want to browse more compounds → All compounds
Unapproved compound: FDA compounding status pending review
BPC-157 is not FDA-approved as a finished drug product. It was removed from the FDA’s Category 2 restricted 503A bulk substances list on April 22, 2026, but that is not the same as approval — it sits in a regulatory gray zone pending the FDA Pharmacy Compounding Advisory Committee’s (PCAC) scheduled July 23–24, 2026 review.
- Research-use-only (RUO) product is not legally intended for human consumption.
- Human clinical trial data is essentially absent; this profile is not a self-treatment guide.
- Banned year-round under WADA’s S0 category for competitive athletes.
Regulatory status
2026 federal and state regulatory context
Not FDA approved as a finished drug product; RUO labeled product is not legally intended for human consumption. Banned year round under WADA's S0 category.
Regulatory changelog
- 2023 04/2026: FDA Category 2 restricted (503A bulk substances). 2026 04 22: Removed from Category 2 (gray zone, not Category 1 approved). 2026 07 23/24: FDA PCAC scheduled to review for 503A compounding eligibility, alongside KPV, TB 500, and MOTS C.
Quick Stats
Evidence level
Preliminary evidence
Typical onset
Varies by prep
Safety rating
Use extra caution: Safety review pending
Best for
Angiogenesis Promotion (VEGFR2 Upregulation), Nitric Oxide Pathway Modulation, FAK Paxillin Growth Factor Signaling
Avoid / review if
Active Cancer Or Cancer History (Theoretical Angiogenesis/Tumor Growth Concern), Pregnancy/Breastfeeding, Unsupervised RUO Product Use Without Physician Oversight
Safety & Cautions
Review before use if any apply: Active Cancer Or Cancer History (Theoretical Angiogenesis/Tumor Growth Concern), Pregnancy/Breastfeeding, Unsupervised RUO Product Use Without Physician Oversight.
Evidence Summary
C PreliminaryEvidence lens
Early signal that needs stronger human replication before practical claims.
Human clinical evidence: Not the primary signal
Mechanistic / preclinical: Mechanism mapped — Angiogenesis Promotion (VEGFR2 Upregulation) · Nitric Oxide Pathway Modulation · FAK Paxillin Growth Factor Signaling
Research maturity: Preliminary or mixed — main contexts: Angiogenesis Promotion (VEGFR2 Upregulation) · Nitric Oxide Pathway Modulation · FAK Paxillin Growth Factor Signaling
Safety boundary: Safety note available — Review before use if any apply: Active Cancer Or Cancer History (Theoretical Angiogenesis/Tumor Growth Concern), Pregnancy/Breastfeeding, Unsupervised RUO Product Use Without Physician Oversight.
Confidence estimate based on the design quality and consistency of published clinical trials.
BPC 157 has a preliminary evidence evidence rating.
How evidence grades work
Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.
Strong
Multiple RCTs, consistent direction, adequate effect size
Moderate
Some RCTs or consistent observational data in humans
Preliminary / Mixed
Animal or in-vitro only, or conflicting human data
Traditional / Theoretical
Traditional use only; no controlled human trials
How BPC 157 Works
Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.
Mechanism Pathway — How BPC 157 Works
Mechanisms & Biological Pathways▼
Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.
Compare & Sourcing
Compare side-by-side tradeoffs or verify active marker guidelines.
Free safety checklist
Get the BPC 157 evidence notes
Occasional research updates, safety context, and product-quality checks for supplement decisions.
We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.
⚠️ Sourcing Options Disabled for Safety
Direct product recommendations and affiliate links are suppressed for this compound due to its high caution or needs-review safety classification.
Evaluate the safety checks, contraindications, and potential medication interactions below under clinician supervision before use.
Safety first · Harm reduction
This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.
Learn how we evaluate confidence, safety, and intensity on the methodology page.
Editorial Review
Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.
Compound profile context
How to interpret BPC 157
BPC 157 dosage by use case, onset and duration, safety limits, and interactions for angiogenesis promotion (vegfr2 upregulation), graded against research.… Use this compound profile to understand mechanism, evidence quality, and practical safety context before comparing products or building a stack. A biochemical pathway connection can be useful for discovery, but it is not the same as proven benefit in humans.
When reviewing BPC 157, separate the active molecule from the product category around it. Dose form, absorption, extract standardization, medication interactions, and individual sensitivity can change the real-world risk-benefit picture.
For supplement planning, avoid combining multiple compounds with overlapping sedating, stimulating, serotonergic, blood-pressure, anticoagulant, or liver-metabolism effects unless a qualified clinician has reviewed the context.